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ABSTRACT
Renick, Paul James Rhodes. M.S. in Microbiology and Immunology, Wright State University.
2002.  CD28 Costimulation Requirement for Interferon-γ Secretion by Natural Killer T cells During
Hepatitis B Virus Infection.
Natural Killer T cells (NKT cells) are a unique subset of lymphocytes that express natural killer
(NK) and T cell receptors (TCR).  The NKT cell population includes four separate subclasses.
This paper will focus on Category I NKT cells which possess a canonical TCR receptor
(Va14Ja281) that recognizes only hydrophobic antigens presented by CD1d molecules.  These
cells are believed to play an important regulatory role in immunity.  A variety of disease
conditions, including cancer, infections and Type I diabetes, are controlled by NKT cells.  NKT
cells are also capable of secreting large quantities of cytokines, namely interleukin-4 (IL-4) and
interferon-gamma (IFN-γ).  This ability to switch between Th1 (IFN-γ) and Th2 (IL-4) cytokines
emphasizes the immunological regulatory role that these cells play.  The mechanisms by which
NKT cells select the cytokines they secrete are not well characterized.  Blocking of CD28 by
monoclonal antibodies or mutation of the CD28 gene impairs NKT cell s ability to secrete IFN-γ in
vitro.  NKT cell of IFN-γ secretion plays a significant role in the clearance of Hepatitis B virus
(HBV) in a HBV transgenic mouse model.  Abrogating or blocking expression of CD28 should
significantly impair the ability of NKT cells to clear HBV infection.  This thesis suggests a series of
in vitro and in vivo experiments designed to test the role of CD28 in IFN-γ secretion and HBV
clearance in mice.
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ABBREVIATION LIST
α-GalCer Alpha-Galactosylceramide iTCR Invariant T Cell Receptor
α-
ManCer
Alpha-Mannosylceramide ITIM Immunoreceptor tyrosine kinase
inhibition motif
APC Professional antigen presenting cell KAR Killer Activation Receptor
CD Cluster of Differentiation KIR Killer Inhibitory Receptor
CD154 CD40 ligand (CD40L) KO Knockout
CD80 B7.1 MCII MHC Class II compartment
CD86 B7.2 MHC Major Histocompatability Complex
CTL Cytotoxic lymphocyte NK Natural Killer
DC Dendritic Cell NKT
cell
Natural Killer T cell
DN Double Negative PAMP Pathogen associated molecular
marker
DP Double Positive PRR Pattern recognition receptor
GPI Glycosylphosphatidylinositol Tc Cytotoxic lymphocyte
HBV Hepatitis B virus TCR T Cell Receptor
IDDM Insulin dependent diabetes mellitus Th T helper
IFN-γ Interferon gamma Th1 T helper 1
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activation motif
Th2 T helper 2
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INTRODUCTION
The immune system is made up of two components: the innate and the adaptive immune
responses.  Components of the innate immune system (e.g. macrophages, dendritic cells, and
NK cells) activate and complement the adaptive immune system.
Cells of the innate immune system take up foreign antigens by germ-line encoded pattern
recognition receptors (PRRs).  The PRRs target groups of highly conserved pathogen associated
molecular patterns (PAMP) such as lipotechoic acid and mannose derivatives (1), which are
typically found in invading pathogens.  These immune responses are low affinity and do not result
generate immunological memory.  The MHC and CD1 surface molecules of professional antigen
presenting cells (APCs) of the innate immune system can combine foreign antigens (2, 3, 4, 5, 6)
and activate CD8 and CD4 T cells.  By secretion of cytokines (IL-12, IL-18 and IL-10), APCs can
also interact and regulate T cells.  These signals influence the differentiation of T cells into Th1
and Th2 CD4 T cells which regulate cellular and humoral immunity.  The adaptive immune
response targets specific pathogenic antigens with high affinity and results in the generation of
memory cells.  Unlike the innate immune system, the adaptive immune system s responses
improve with each subsequent exposure to a specific pathogen.
A variety of immune cells occupy a position intermediate between the innate and adaptive
immune systems.  These cells play a role in regulating and directing the subsequent adaptive
immune response.  These immune cells are B-1 B cells, γδ-T cells and Natural Killer T cells (NKT
cells).
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Natural Killer T cells
NKT cells are a subset of lymphocytes, found in mice and humans (7) that possess
characteristics of the both innate and adaptive immune cells.  These cells are implicated in
shaping immune responses to different pathogens.  NKT cells express both T cell receptors
(TCR) and natural killer (NK) receptors.  There are 4 groups of these cells differing in TCR
restriction; NK marker expression and surface marker expression (see Table 1).
Category I of NKT cells possesses an invariant TCR (iTCR) comprised of Vα14Jα281
chain paired with a Vβ8.2, Vβ7 or Vβ2 chain (8, 9, 7).  The cells bearing iTCR are CD1d restricted
and display either a CD4 co-receptor or no co-receptor (double negative).  This type of
NKT cell does not express
CD8 surface molecule but
usually express NK1.1 (10,
11).
Type II NKT cells are CD1d-
reactive and are double
negative (DN) or CD4+ (12,
10).  The TCR is classified
as semi-diverse and
express either
Vα3.2Jα9.Vβ8 or Vα8/Vβ8 (7).  The third category of NKT cells is CD1d-independent and display
on their surface either CD4, or CD8 or no co-receptor (DN).  Category III NKT cells, enriched in
the bone marrow and spleen, express a na ve T cell phenotype and are thymus-independent in
their development (12, 10, 13).  The fourth population of NKT cell is characterized by the
expression of CD49B (a ligand for DX5).  Category IV NKT cells are believed to play a role in
antigen-specific immune responses in irradiated skin and in suppression of Type I diabetes (7).
Category I NKT cells
Table 1- Categories of murine NKT cells (Adapted from Kronenberg
et al 2002 (7))
Category I II III IV
Repertoire
Vα14-Jα18
Vβ8.2/7/2
Semi-diverse
Vα3.2-
Jα9/Vα8,
Vβ8
Vα diverse
Vβ diverse
Vα diverse
Vβ diverse
Co-receptor CD4+ or DN CD4+ or DN CD8
+, CD4+ or
DN
CD8+, or
CD4+
Reactivity α-GalCer ND Self-agonist ND
Antigen-
presenting
molecule
CD1d CD1d MHC Class I
MHC Class I
and MHC
Class II
NK receptors
DX5-
Mostly NK1.1
DX5 (?)
Mostly
NK1.1+/-
DX5+/-
Mostly NK1.1+
DX5+
Mostly
NK1.1+/-
Location
Thymus, liver,
spleen and
bone marrow
Thymus (?),
liver, spleen
and bone
marrow (?)
Liver, spleen
and bone
marrow
Thymus  (?),
liver, spleen
and bone
marrow
No J region indicated T cell receptors are diverse, α-GalCer- α-galactosyl ceramide; DN,
double negative; J joining region; ND, not determined; NK natural killer; V, variable
region)
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This thesis focuses on Category I NKT cells (referred to hereafter as NKT cells).  These
cells are either CD4+ or DN paired with an iTCR (Vα14Jα281 /Vβ8.2, 7 or 2) that is CD1-
restricted.  NKT cells possess an activated T cell phenotype (i.e. CD69+, CD44high, CD62L, CD5
high, CD45RBhigh and IL-2R),
which is also indicative of a cell
type that can rapidly respond to
environmental stimuli (8, 12).
These cells express NK
receptors and the most prevalent
markers are NK1.1, CD122 and
Ly49 membrane molecules.
NKT cells are noted for their
rapid secretion of high levels of
IL-4.  NKT cells secrete INF-γ as
well as a wide variety of other Th1, Th2 and Th3 cytokines (8, 9, 7, 12).  NKT cells are widely
distributed through the body, but the ratio of NKT to T cells varies with tissue.  In mice, NKT cells
are most prevalent in the thymus (~15%), bone marrow (~25%) and thymus (~40%).  NKT cells
are least prevalent in the spleen (3%), lymph nodes (0.3%), blood (4%) and lungs (7%) (9 13,
12).  Like conventional T cells, maintenance of NKT cells occurs independently of the thymus.
The bone marrow plays a major role in replenishing NKT cells after activation-induced death (9,
14).
Human NKT cells
NKT cell subsets of humans have the same characteristics as murine NKT cells
(See Table 2).  Human type I NKT cells also have an iTCR comprised of Vα24JαQ paired with
Vβ11.  The human NKT cells also possess an invariant TCR comprised of the Vα24JαQ α chain
Table 2- Characteristics of murine and human category I
NKT cells (Adapted from Kronenberg et al, 2002 (7))
Characteristics Mouse Human Comment
Major Subset CD4+, DN CD4+, DN Proportions vary
T cell receptor
α-chain
β-chain
Expression level
Vα14Jα281
Vβ8.2, 7,2
Intermediate
Vα24JαQ
Vβ11
Intermediate
Homologous
Homologous
Accessory
molecules
NK associated
NK1.1,
CD122, Ly49
NKR-P1,
CD122
Homologous
(CD161)
Restriction element CD1d CD1d Homologous
Cognate antigen Glycolipid Glycolipid
α-GalCer
stimulates
Cytokine production
IL-4
IFN-γ
Rapid high
levels
+
Rapid high
levels
+
Following TCR
ligation
Following TCR
ligation
Frequency
PBL ~1% ~0.1-0.5% Move variable inhumans
α-GalCer- α-galactosyl ceramide; PBL- peripheral blood lymphocytes
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as well as a conserved β chain Vβ11.  These iTCR are also CD1d restricted like their murine
counterparts.  The distribution in humans is not as clear, with most studies limited to the
peripheral blood, but NKT cells are reported to be located in the liver (9).  A major difference
between human and murine NKT cells is that human category I NKT cells are separated into two
distinct functional subsets; CD4+ and DN NKT cells.
The CD4 subset is polarized towards predominantly Th2 cytokine secretion (IL-4) with
some Th1 cytokine secretion.  These cells play a regulatory role in immune tolerance (15, 16, 17).
The DN subset secretes Th1 cytokines (IFN-γ) and function in responding to infection and
inflammation (15, 16, 17).
In addition, these
subsets differ in chemokine and
NK marker expression.  Each
subset possesses distinct
chemokine receptors and T cell
cytokine profiles (See Table 7) (18).  CD161 and CD65 membrane markers are expressed by
Human CD4 NKT cells (See Table 3) (18).
Murine and human NKT cells play similar roles in associated autoimmune disorders.
Mouse NKT cell models exist for Type I diabetes, systemic erythematosis lupus, and systemic
sclerosis (see NKT cells and Immunity).  Consequently, mouse models of NKT cell responses are
important in understanding the roles of human NKT cells in immune regulation.  Human and
mouse NKT cell iTCR and CD1d are so highly conserved between the two species that mouse
CD1d is capable of activating human NKT cells and human CD1d is capable of activation of
mouse NKT cells (5).  This indicates that the evolutionary pressures that maintain the conserved
nature of CD1d and iTCR are at least partially shared between humans and mice.
Table 3 — A comparison of Human NKT cell subset
chemokine receptors and NK receptors (Data from Lee et al,
2002 (15), Kim et al, 2002 (17) and Gumperz et al, 2002 (16))
NKT cell
Subset
Exclusively
CD4
Exclusively
DN
Both CD4 and DN
Chemokine
Receptors CCR4
CCR1
CCR6
CXCR6
CCR1
CCR2
CCR5
CXCR3
CXCR4
CXCR6
NK markers
2B4
CD94
NKG2A
CD161 (CD4 lower
frequency than DN)
CD56
6
NKT CELL DEVELOPMENT
NKT cells develop in a manner similar to conventional T cells (7, 20, 21) and derive from
common lymphoid progenitor
cells that migrate to the
thymus.  Upon reaching the
thymus, conventional T cells
develop from double negative
(DN) thymocytes to double
positive (DP) thymocytes by
successfully expressing TCR
and co-receptors.  Those DN
thymocytes that do not
successfully express TCR die
of neglect (apoptosis).  This
selection is mediated by cortical epithelial cell and results in single positive thymocytes (SP)
expressing either the CD4 or the CD8 co-receptor.  The DP thymocytes undergo two selection
events, positive and negative selection.  Positive selection takes place in the cortex of the thymus
with cortical epithelial cells.  DP thymocytes that can recognize and loosely bind MHC class I or II
survive and migrate to the medulla, while those that do not recognize MHC complexes undergo
apoptosis.  Negative selection occurs in the medulla of the thymus, eliminating auto-reactive
thymocytes that tightly bind to MHC and self-antigen. These na ve T cells then migrate to the
periphery.  T cell maturation results in apoptosis of 95% of the thymocytes that enter the thymus
from the bone marrow.
Figure 1- Asymmetric re-expression of CD4 and CD8
(Adapted from Lucas et al, 1996 (19))
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T cell Co-receptor Selection
The mechanism of co-
receptor selection by DN thymocytes is
poorly understood.  The instructive
theory states that DP thymocytes
receive a distinct signal from cortical
epithelial cells to become committed to
the CD4 or CD8 pathway, down-
regulating the expression of opposing
co-receptor.  Stochastic development,
maintains that the selection of lineage is
a random genetic choice independent of
external signals.  Because of this
genetic selection the opposing co-
receptor is no longer expressed. Under
this system some DP thymocytes will
inappropriately select the wrong co-
receptor and thus be eliminated by apoptosis.  Several different types of studies were undertaken
to test both theories (21).
The instructive theory is supported by rescue experiments in which thymocytes that
selected the wrong co-receptors were not rescued by the transgenic expression of the
appropriate MHC molecule.  In these experiments, expression of one type of TCR (CD4 or CD8)
was enforced throughout T cell development in addition to the randomly selected co-receptor.  If
the stochastic theory were correct, then T cells that chose an incorrect co-receptor should be
rescued by this enforced expression.  The end result would be CD4 and CD8 (DP) mature
thymocytes.  In the initial experiments, no mature DP T cells were generated (21).  These
observations support the instructive theory.
Figure 2- Strength of Signal Model (Adapted from Germain et al,
2002 (21))
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Data supporting stochastic development came from phenotypic analysis of MHC knock
out (KO) mice. Two different KO mice were developed displaying two distinct DP thymocyte
phenotypes: CD4med, CD8high (MHC II -/-) and CD4high, CD8med (MHC I -/-).  These transitional
states were not expected since the deficient MHC was not present to instruct  development T
cell development.  The opposing co-receptor (CD4 in MHC I KO mice or CD8 in MHC II KO mice)
expression was eventually extinguished (21).  These observations supported the stochastic
model.
Germain et al
discovered that both CD4
and CD8 SP thymocytes
derive from CD4high, CD8med
DP thymocytes and that co-
receptor extinction is not
linear (19).  These data
demonstrate that both co-
receptors are lost on TCR
signaling and the extent of
that loss is determined by
signal strength.  Both of the
co-receptors are then re-
expressed in an asymmetric
manner, first CD4 then CD8
giving rise to the observed
CD4high, CD8med DP
thymocytes.  After this re-expression, the inappropriate co-receptor is extingished (Figure 1).
Germain et al have proposed a modification of the instructional development model and refer to
this model as the strength of signal model (Figure 2) (21).
Figure 3- The NKT cell Developmental Pathway (Adapted from
Kronenburg et al, 2002 (7))
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According to the strength of signal theory, CD4 and CD8 commitment depends on the
duration and intensity of the signaling from the TCR.  Short duration signaling leads to CD8
commitment and long duration signaling leads to CD4 commitment.  Selection of CD4 expression
is based on the association of the tyrosine kinase Lck with this co-receptor (21).  In this model
some DP thymocytes will have TCR that weakly bind to MHC class II, resulting in selection of
incorrect CD8 choice while other DP thymocytes will have TCR that bind strongly to MHC class II,
resulting in incorrect CD4 choice.  Both of these events would be fairly rare and cells exhibiting
these choices undergo apoptosis.  In experiments in which recombinant receptor studies in which
the intracellular domains of both CD4 and CD8 were exchanged, lineage fate was controlled by
the intracellular signaling end of the co-receptor.  MHC II specific thymocytes in the absence of
cells expressing CD4 developed into CD8 thymocytes.  At low concentrations of phorbol ester or
ionomycin, CD8 T cells were produced and at high concentrations of these drugs CD4 T cells
were produced.  Cross-linking experiments in which the TCR of double positive thymocytes were
cross-linked with CD4 or CD8, or TCR generated single positive thymocytes with up to a 90%
transition rate.  Kinetic labeling studies of the selection efficiencies of CD4 and CD8 T cells
resulted in selection rates of up to 40% for CD8 T cells and 90% for CD4 cells (22).  These
observations favor an instructive model over a stochastic model.
NKT cell Development vs. Conventional T cell Development
NKT cells follow a similar developmental pathway as T cells but with some differences
(see Figure 3).  Thymectomized neonatal mice show depletion of NKT cells (24).  An intact thymic
structure is also required (25).  In mice with defective thymic structure (e.g. aly/aly mice), NKT
cells are depleted, while conventional T cells are not. Aly/aly mice have a poorly defined cortico-
medullary junction and no clearly defined boundary area.  The medullary area is extremely small
and the medullary epithelial cells are sparse and in the cortex there are thicker and more
abundant reticular fibroblasts than with aly/+ mice.  Vα14-Jα281 transcripts were only found in
the thymus of mice and not in the bone marrow (a proposed alternative development site) (26).
Within the thymus NKT cell precursors (NK1.1- CD4+) have been detected using CD1d-α−GalCer
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tetramers (11).  Unlike conventional T cells, NKT cells are selected by CD1d DP thymocytes (27,
28).  CD8 expression results in apoptosis (9, 7).  Following the strength of signal model, NKT
cells that receive a frequent and long to moderate intensity signal probably develop into CD4 NKT
cells, while those that receive a short/low intensity signal become double negative (DN) NKT
cells.  However, such events have not been observed and are only speculation.  A variety of
mutations affect the development of NKT
cells (see Table 5).  Deletion of CD1d
results in depletion of NKT cells (29, 30,
31) and, like conventional T cells, NKT
cells require successful expression of
both pre α-chain and iTCR (32, 33).
Unlike conventional T cells, NKT cells do
not appear to undergo negative selection
(7, 9) and these potential autoreactive
cells are most likely kept in check by their
KIR receptors (7).
The cytokines crucial for NKT cell development are IL-7 (9), (7), IL-15 (9, 7) membrane
lymphotoxin (Ltα/β) (39, 40) and granulocyte macrophage colony stimulating factor (GM-CSF)
(34).  Mice in which expression of capthesin S gene is disrupted have impaired NKT cell selection
and function (41).  Expression of common γ-chain is also required for NKT cell development (7).
Like conventional T cells; NKT cells require both RAG-1 and 2 for successful TCR expression (9).
NKT cells, unlike conventional T cells, are also dependent on Fyn signaling (36, 37) for proper
development yet are unaffected by dnRAS and dnErk knockouts (38) which are essential for
conventional T cell development.  Knockout of expression of the wing-helix-turn-helix transcription
factor Ets-1 results in depletion of NKT cells (35).
Table 4 — NKT cell developmental mutations
(Adapted from Kronenburg et al, 2002 (7))
Genetically
modified KO mice Change in cell number References
T
cells
NKT
cells
NK
cells
Common γ-chain -- -- -- (7)
IL2r +++ -- -- (7), (9)
IL7 -- -- +++ (9)
IL15 +++ -- -- (7), (9)
GM-CSF +++ -- +++ (34)
Ets1 +++ -- -- (35)
Fyn-/- +++ -- +++ (36), (37),(38)
Lta/b-/- +++ -- -- (39), (40)
Aly/aly +++ -- -- (25)
Jα18-/- +++ -- +++ (7), (9)
CD1d-/- +++ -- +++ (29), (30)(31)
DnRAS/dnERK -- +++ +++ (38)
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NKT CELLS AND CD1D
The CD1 family is a group of nonclassical (Class Ib) MHC molecules originally
discovered using monoclonal antibodies (42).  This family of molecules presents hydrophobic
antigens (lipids and peptides) (43) to the immune systems and has been referred to as the third
antigen-presenting pathway.  The discovery of this system also showed new roles for T cells in
adaptive cellular immunity: the recognition of non-self glycolipid antigens and elimination of
associated pathogens and targeting of altered self.  This process of lipid antigen presentation
closely parallels traditional peptide antigen presentation and utilizes similar intracellular
compartments (44, 45, 41).  CD1 genes show a lack of polymorphism (5, 3).  This lack of diversity
suggests that there are distinct evolutionary pressures to conserve these genetic sequences.
CD1 molecules also have a role in presenting self-antigens to the immune system, suggesting
they play a role in immune regulation and tumor surveillance (44).
CD1 Characteristics and Intracellular Trafficking
The CD1 family of molecules is comprised of five isoforms each encoded by individual
genes.  These genes share many characteristics of MHC class I genes such as the intron/exon
structure and their homology of the polypeptides to the MHC Class I gene products.  Encoded by
the CD1 genes are a leader peptide, 3 extracellular domains, a transmembrane region and
carboxy terminus region.  The isoforms are split into 2 groups: Group 1 is comprised of CD1a, b,
c, e and Group 2 comprised of CD1d.  The classification is based on homology of the nucleotide
and amino acid sequence and is supported by expression and function of the groups (3). Based
on the highly conserved nature of the α3 region coded on all CD1 molecules, the CD1 isoforms
can also be considered members of immunoglobulin
12
 superfamily (47).  Secreted forms of CD1 have been characterized but the function of these
soluble products in unknown (42).  Mapping of the CD1 family has proven difficult due to multiple
transcripts, poorly defined initiation sites and extensive alternative splicing (42).  NKT cells
recognize lipid antigens presented by CD1d molecules.
Group II (CD1d) molecules are expressed on all hematopoietic stem cells,
gastrointestinal epithelial cells and most murine B cells, on human and murine thymocytes, on a
subset of human T and B-lymphocytes and resting monocytes (3). While the CD1 family is
structurally similar to the MHC class I molecules, antigen processing and presentation are similar
to those of the MHC class II molecules.
The crystal structure of
murine CD1d has been determined
and the organization and folding is
similar to MHC class I molecules.
CD1d is a heterotetrameric structure
comprised of 3 ~50 kDa heavy
chains (α chains) associated with β2
microglobulin (β2M).  The
association with β2m is essential for
antigen presentation by CD1d (See
Figure 4).  Subtle differences
between the CD1d structure and the MHC class I molecule exist, there is no single turn α1 H1
helix of class I molecules and CD1d has a different arrangement in the bulge of the β2m S4
strand compared to H-2K.  The binding pocket of CD1d is extremely hydrophobic as determined
by electrostatic potential mapping (47).  The CD1d binding groove is the largest of any MHC
antigen-presenting pocket whose structure has been determined.  The binding groove of CD1d is
narrower and has near constant width in contrast to the MHC Class I and II molecules (47).
Proposed binding of glycolipid antigens occurs by insertion of the hydrophobic tail of the antigen
Figure 4-The crystal structure of murine CD1d (Adapted
from Zeng et al, 1997 (47))
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into the binding pocket leaving the polar head of the molecule exposed to interact with the TCR
(47).
CD1d molecules enter the MHC II compartments (endosomes and lysosomes referred to
as MCII) to bind to their respective antigens (see Figure 5).  CD1d is found in LAMP-1+
compartments (late endosomes/lysosomes) (3, 45).  Cells treated with either chloroquine or
conacanmycin A show lose the ability to present lipid antigen.  Both of these drugs neutralize the
acidic pH of endosomes interfering with the antigen presentation by MHC II.  The increase in the
pH of the endosomes prevents the effective degradation of the pathogens into presentable
molecules that can complex with
MHC or CD1.  CD1d possess a
tyrosine-targeting motif on the C-
terminus which interacts with a
small group of cytosolic adapter
proteins responsible for cellular
sorting events.  These proteins
are referred to as AP-1 and AP-2.
AP-1 is located at the
cytoplasmic face of the trans-
Golgi network and AP-2 is located mainly in the plasma membrane and is required for the
internalization of proteins from clathrin coated pits and vesicles leading to the endocytic pathway
(45).  The adapter protein with which CD1d interacts is not known (6).
CD1 antigen-binding functionality depends in some manner on the invariant chain (Ii) (45,
18, 41).  Removal of the cytoplasmic tail of CD1d causes redirection of CD1d to the cell surface,
while this effect can be reversed by the co-expression of Ii.  In Ii -/- mice CD1d was widely
distributed to the cell surface and APCs for these mice do not optimally stimulate autoreactive
NKT cell hybridomas (45). These observations suggest that a ligand must be optimally loaded.  In
immunoprecipitation with anti-CD1d antibody experiments, Ii was found with a fraction of CD1
molecules (45).  Mice deficient in cathepsin S exhibit a reduced number of CD1 restricted NKT
Figure 5- CD1 and MHC intracellular trafficking (Adapted
from Goldsby et al, 2000 (48))
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cells.  Cathespin S plays a role in the degradation of Ii, suggesting a link between CD1d and Ii
(41).
Antigens presented by the CD1 family include glycolipids (diacylglycerols, sphingolipids,
polyisoprenoids or mycolates) (49, 44, 50, 18).  Lipid length plays a role in endosomal entry and
antigen presentation by CD1b (51, 52).  Typically long alkyl chains indicative of microbial
glycolipids (e.g. a C80 alkyl chain) are delivered to the late endosomes several hours post uptake,
but a shorter C32 chain on the same antigen is rapidly and inefficiently presented by surface
CD1b.  Dendritic cells (DCs) preferentially present long chain antigens with chain length
determining T cell stimulation potential.  Minimum antigen length for T cell activation is 12
carbons.  These observations support the hypothesis that DCs utilize a specialized endosomal-
loading pathway to promote preferential recognition of microbial glycolipids (52).
Currently, only mycobacterial antigens are known to be presented by CD1 molecules
(CD1b and CD1c) (44, 5, 3, 53, 43, 54)(44).  While activation of CD1 restricted NKT cells via
CD1d antigen presentation has not been directly observed in vivo, several in vitro systems have
demonstrated this effect (8, 9, 7, 47, 55).
Currently, most in vitro systems study NKT cell
activation using α-galactosylceramide (α-GalCer), a marine
sponge derivative (5) (see Figure 6).  While this substance
does not represent a natural ligand for CD1d, it is able to
activate NKT cells and may be an analog of undiscovered
ligand (49).  Following infection by bacteria, parasites and
viruses, α-GalCer has stimulated NKT cells to respond (8,
7, 9).  Alpha-galactosylceramide has also stimulated strong anti-tumor responses by NKT cells.
CD1d:α-GalCer tetramers are used to quantify the numbers of NKT cells (56).
Another suspected CD1d ligand is glycosylphosphatidylinositol (GPI) but this has not
been conclusively demonstrated (57, 58)
Figure 6- The structure of
alpha-galactosylceramide
(Adapted from Calabi et al, 2000 (42))
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NKT CELLS AND IMMUNITY
NKT cells play a role in
immunity against a variety of
bacterial, parasitic and viral
infections.  NKT cells may either
direct or aid in anti-tumor responses.
NKT cells drive of aid in the induction
of tolerance (e.g. anterior chamber
acquired immune deviation) and play
an important role in immune
regulation (e.g. Th2 induction).
Immune Regulation
The explosive secretion of
IL-4 by NKT cells helps polarize T
helper cell function and cytokine
secretion towards a Th2 cell
response and down-regulates any
Th1 cell response.  NKT Th1
cytokine secretion may not drive Th1
polarization but may activate other
immune cells that can polarize the
immune response to a Th1 profile.  In this manner, NKT cells play a supporting role in Th1
Table 5- NKT cells and Immunity (Adapted from Godfrey et
al 2000 (9))
Immune Regulation
Induction of Th2 response Aid in generation by massive IL-4
secretion
Anterior chamber acquired
immune deviation (ACAID)
NKT cells are required to generate
negative effector CD8 T cells
Graft vs. Host Disease NKT cells are required for prevention
Suppression of anti-tumor
response
NKT cells are required to generate
negative effector CD8 T cells
Autoimmunity
Type I Diabetes NKT cells are deficient in NOD mice,
BB rats and human diabetics
Lupus Decrease in NKT cells associated with
pathogenesis (mice and humans)
Multiple sclerosis Decrease in NKT cells associated with
pathogenesis (mice and humans)
Systemic sclerosis Decrease in NKT cells associated with
pathogenesis (mice and humans)
Experimental autoimmune
gastritis
Thymectomy in 3 day old mice
depletes NKT cells
Anti-metastatic activity
IL-12 mediated rejection Low dose IL-12 activates NKT cells to
direct anti-tumor responses
α-GalCer mediated rejection Activates NKT cells to direct anti-
tumor responses
Natural rejection APCs activate NKT cells to direct anti-
tumor responses in MCA induced
tumor models
Infection
Bacteria:
Listeria
Mycobacteria
Psuedomonas aeroginosa
NKT cells aid in clearing infection
NKT cells needed for granuloma
formation and switch to IFN-γ
production
NKT cells serve as sentinel cells and
activate effector cells
Eukaryotic Pathogens:
Toxoplasma
Plasmodium
Cryptococcus neoformans
Brugia pahangi
NKT cells needed to generate CD8
effector T cells
Inhibit parasite growth, debatable role
in IgG formation
NKT cells recruited to the lungs and
driver Th1 response to pathogen
Source of IL-4 against 3rd stage larvae
Viruses:
Diabetogenic
encephalomyocarditis virus
(EMCV-D)
Hepatitis B
NKT cell activation protects mice from
infection and pathology
NKT cell activation inhibited viral
replication
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induction. NKT cells are required for the induction of peripheral tolerance in the eye.  Anterior
chamber acquired immune deviation (ACAID) prevents damaging Th1 responses in the eye.
Antigen in the eye is taken up by APCs that selectively recruit and activate NKT cells to produce
TGF-β.  TGF-β induces the generation and expansion of antigen-specific MHC Class I-restricted
CD8 T regulatory (Tr) cells.  These Tr cells secrete TGF-β and IL-10 that down-regulate Th1
mediated delayed hypersensitivity reactions (DTH) against the antigen (59, 9).  The transfer of
DN NKT cells to rats that underwent allogenic bone marrow transplantation prevented the
induction of graft vs. host disease (60).  NKT cells also can down regulate anti-tumor immune
responses.  DN NKT cell clones were able to suppress the generation of B16 melanoma specific
CTLs without affecting the immune response against the tumors both in vitro and in vivo (61).
The DN NKT cells were capable of directly lysing the tumor specific CTLs (61).
Autoimmunity
The absence of NKT cells appears to play a role in various autoimmune disorders (62).
NKT cells are depleted in Type I diabetes (IDDM) in both humans and mice (9, 63).  Genetic
analysis of diabetic siblings compared to non-diabetic siblings revealed that the diabetic siblings
show defective generation of NKT cells (64).  Treatment of non-obese diabetic mice (NOD) mice
with a-GalCer prevents the onset of IDDM.  Transfer of NKT cells to transgenic diabetic mice from
non-diabetic mice protects them from developing diabetes (63, 65, 66, 67).
Human patients with multiple sclerosis or systemic sclerosis patients exhibit decreased
numbers of NKT cells in their peripheral blood (68, 69).  Analysis of the thymocytes from the
peripheral blood of systemic sclerosis patients revealed Vα24 T cells with alternate J regions.
These cells show a five-fold increase over the number seen in non-afflicted individuals.  These
data were interpreted to mean that oligoclonal expansion of these cells coupled with a lack of
NKT cells is responsible for the damage caused by systemic sclerosis (69).
Neonatal mice that undergo thymectomies in the 3rd day of life lack NKT cells and
develop a variety of organ-specific autoimmune disorders (gastritis, thyroiditis and reproductive
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organ disorders)(24).  These mice also develop lymphopenia suggesting an increased pathogen
load and loss of Th1 suppression.
In mouse models of lupus erythematoses, depletion of NKT cells gives rise to DN T cells
display heterogeneous TCRs, no NK markers; these cells are restricted to MHC class I,
suggesting a loss of immunoregulatory function (70).  These DN T cells support the production of
the pathogenic anti-DNA antibodies by synergeneic B-cells (69).
Anti-Cancer Responses
NKT cells play a role in tumor destruction in three murine cancer models.  The three
described models are the IL-12 mediated rejection model, the α-GalCer rejection model and the
natural rejection model (71).
In IL-12 mediated tumor rejection, NKT cells are activated and anti-metastatic at low
doses of IL-12 (71, 72, 73).  NKT cells activate NK cells to lyse cancer cells; the roles of
macrophages and CD8+ cytotoxic lymphocytes (CTLs) in this process are not known.  Tumor
lysis requires IL-12, perforin and IFN-γ.  At high doses of IL-12, both NKT cells and NK cells are
activated to produce IFN-γ (74), (71).  CD1d and Rag deficient mice show reduced anti-cancer
responses (75) These observations emphasize the role of NKT cells in IL-12 induced tumor
rejection.
In α-GalCer mediated rejection, α-GalCer is presented by APCs to NKT cell resulting in
activation of the NKT cell.  This activation is enhanced by IL-12 secretion from the APC.  In turn,
the NKT cell secretes IFN-γ which then activates NK cells and further stimulates APC activity.
The role of macrophages and CD8+ CTLs in this model is not clear.  Tumor lysis is IL-12 and
IFN-γ dependent but perforin independent (76, 77, 71, 78).  NKT cells can directly lyse murine
tumor cells in vitro (76).
The natural rejection model was discovered using methylcholanthrene (MCA) induced
tumors.  In this model, endogenous glycolipid antigen (possibly tumor derived) is presented to
NKT cells by APCs.  This model is similar to the α-GalCer mediated rejection model (IL-12 and
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IFN-γ dependent) except perforin is required for tumor lysis.  NK cells and CD8+ CTLs are
activated by IFN-γ to kill the tumors.  In this model, NKT cells are essential for protection
compared to other models where NKT cells are protective only when endogenous IL-12 or is α-
GalCer administered (78).
NKT Cells and Infection
NKT cells play a role in defense against several types of bacteria (8, 9, 7).  NKT cells
play a supporting role in clearing mycobacterial infection (7).  NKT cells are present in tubercular
granulomas, which do not form in NKT cell deficient mice (7, 9).  In addition, NKT cells down
regulate IL-4 production and up-regulate IFN-γ in response to mycobacterial infection.  Despite
these observations CD1d-deficient mice were not less susceptible to infection with mycobacteria,
suggesting that NKT cells play an accessory role rather than driving the immune response
against Mycobacterium tuberculoses (53).  NKT cells also respond to Listeria monocytogenes (8,
9).  CD4 NKT cells were down regulated in an IL-12 dependent manner with a concomitant
increase in DN NKT cells secreting IFN-γ.  In a separate study, Godfrey et al observed an
increase in IL-4 secreting NKT cells in the spleen suggesting that DN IFN-γ secreting NKT cells
respond at the site of infection while IL-4 secreting NKT cells migrate to the spleen to enhance
antibody production (9).  In mice, NKT cells play an important role in the clearance of
Pseudomonas aeroginosa infection from the lungs (79).  The inhibition of Pseudomonas
aeroginosa infection was CD1d dependent, and was enhanced by α-GalCer treatment.  In this
model, the NKT cells served as sentinel cells, which responded to the infection by IFN-γ
secretion, activating avelolar macrophages.
NKT cells have also been implicated in defense against various eukaryotic pathogens
(parasites and fungi).  In experimental murine malaria models, DN NKT cells responded to
infection by IFN-γ secretion (similar to Listeria) (9).  CD1d presentation of sporocyte altered GPI
resulted in the stimulation of NKT cells and a Th2 response to infection (57). This response
appeared to be severely inhibited in CD1d deficient mice (57).  However, several different
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laboratories have not been able to reproduce these data, so the issue is still contentious (58),
(80).  Treatment with α-GalCer does protect against malaria, implicating NKT cells in the
response to this pathogen (81).  In mice, DN NKT cell populations rapidly expand and accumulate
in the spleen and draining lymph nodes during Brugia pahangi infection (within 24 hours).  These
DN NKT cells are a source of IL-4 against the 3rd stage larvae of B. pahangi (82).  NKT cells also
play a role in protecting mice against the fungal pathogen Cryptococcus neoformans (83).  During
infection with this pathogen, NKT cells are recruited to the lungs and drive the Th1 response
against the fungus.  NKT cell deficient mice showed a reduced Th1 response against this
pathogen.  In infection with Toxoplasma gondii NKT cells were implicated in generating CD8
effector cells (8, 9).
In defense against viruses, NKT cells have played a role in host defense in 2 mouse
models.  Treatment with α-GalCer leads to NKT cell activation and amelioration of diabetogenic
encephalomyocarditis virus (EMCV-D) infection in mice (55).  Both CD1d and Jα281 KO mice
were not protected from infection.  In the second model, replication of hepatitis B virus was
inhibited by a-GalCer activation of NKT cells (84).  Inhibition of viral replication was dependent on
IFN-γ and IFN-α/β as determined with KO mice.  Activated NKT cells secrete IFN-γ, which then
activates NK cells to secrete antiviral cytokines.
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NKT CELL NK AND T CELL RECEPTORS
NK Receptors Expressed by NKT cells
NKT cells express several families of NK receptors on their surfaces (see Table 4).  NK
receptors can be grouped into two types, killer activation receptors (KAR) and killer inhibition
receptors (KIR).  KAR possess an immunoreceptor tyrosine kinase activation motif (ITAM)
delivering a signal to kill the targeted cell.  When the KARs are activated various tyrosine kinase
(PI3, Zap-70 and Syk kinases) are recruited and phosphorylated thus activating signal
transduction pathways.  This signaling results in the re-direction of the cellular secretion
apparatus, stimulating release of granzyme/perforin that kills the target cell.  Another effect of the
activation of this receptor is the secretion of pro-inflammatory cytokines.  KIR receptors recognize
MHC Class I molecules.  MHC I bind KIR resulting in the activation of SHP-1/2 phosphatases.
These phosphatases dephosphorylate essential signal kinases (e.g. ZAP-70 and Fyn) interrupting
the activation signaling cascades.  This results in secretory killing mechanism being shut off.
Consequently, these two receptors regulate NK killing by balancing both positive and negative
signaling.  Many of these receptors are among the Type II lectin superfamily and are located in a
gene cluster in both mice and humans referred to as the NK gene complex (85, 86).
The most significant NK marker on NKT
cells is NK1.1 in mice and humans (CD161).
There are 3 isoforms reported in mice and a single
analog in humans.  These markers are members
of the C-type lectin family and function as KAR
receptors.  The exception to the rule is the B isoform of NK1.1 that possesses an ITIM region thus
serving as a KIR receptor.  All of the 3 isoforms express the CxCP motifs that have been
Table 6- NK receptors expressed by
NKT cells (Adapted from Lanier et al, 1998 (85))
C-Type Lectins Immunoglobulin Superfamily
NK1.1 (NKR-P1)
Ly49
CD94/NKG
NKG2D
CD16
Ly6
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shown in rats to interact with p56lck (85).  This tyrosine kinase is also known to play a role in TCR
signaling and cytokine secretion.
The Ly49 family is another major family of NK receptors expressed on NKT cells.  There
are multiple isoforms of this gene in mice coding for Isotypes A-I.  Products of these genes
display a wide diversity of cytoplasmic and extracellular domains, suggesting a multiplicity of roles
in ligand binding and signal transduction.  These receptors recognize H-2 class I molecules on
possible target cells and inhibit cytotoxic activity upon recognition of self.  These receptors
possess ITIM motifs that inhibit activation of cytotoxic effector function.  The exception is the
Ly49H isoform that was recently implicated in the activation of NK cell cytotoxicity (87).
The NKG2 family is similar to the Ly49 family and has been implicated in the recognition
of polymorphic HLA I molecules.  These receptors, unlike other members of the Type II lectin
family, are expressed as heterodimers on cell surfaces (86, 85).  The exclusive partner molecule
is CD94, encoded by a single gene with limited polymorphism.  The role of CD94 is unknown; it
has no cytoplasmic domain and thus no role in signal transduction.  NKG2 proteins cannot be
expressed unless paired with CD94, thus CD94 might serve as a chaperone (85).  The NKG2
family is comprised of 5 genes (NKG2A, NKG2B, NKG2C, NKG2D/F and NKG2E) (86).  The
cytoplasmic domains of these proteins are different, suggesting diverse ligand and signal
functions.  NKG2D also varies in its cell surface expression and is expressed as a homodimer
independent of CD94.  It is comprised of 2 β sheets, 2 α helices, 4 disulfide bonds and a β strand
which distinguishes it from other C-type lectin receptors (86, 88).  Ligands for this receptor in
mice are RaeI and H60 and in humans, MICA, MICB and ULBP (89).  These ligands are typically
induced and/or up regulated in response to cellular distress (86).  Viver et al have proposed that
NKG2D might serve a role in both NK cell activation and as a co-stimulatory molecule in T cells
(86).  Activation of NKDG2 in NK cells leads to cytotoxicity, proliferation, survival, cytokine
production, chemokine production and tumor lysis.  These observations support the hypothesis
that NKG2D is a primary receptor for cytotoxicity and a co-stimulatory molecule for cytokine
secretion (86, 90, 89).
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CD16 (FcγRIII), one of the most extensively studied NK receptors, is a low affinity
receptor for IgG.  It is a member of the immunoglobulin superfamily and is expressed as a ~70
kDa glycoprotein.  The cytoplasmic domain of CD16 has an ITAM, thus serves as a KAR
receptor.  The signal transduction pathways of CD16 are similar to the activation pathways of the
T cell receptor (TCR).  CD16 activation results in cytokine secretion, mediation of antibody-
dependent cellular cytotoxicity (ADCC) and may signal apoptosis (85).
Three other receptors expressed on the surface of NKT cells have effector functions
similar to CD16.  These 3 receptors are Ly6, CD69 and CD44 and are reported to cause the lysis
of Fc receptor bearing target cells (85).
Like NK cells, NKT cells are capable of lysing targeted cells through both the secretory
and non-secretory pathways
(92).  Killing of targeted cells by
the non-secretory pathway is by
Fas/FasL interaction.  This
interaction signals the activation
of caspases, resulting in
apoptosis.  Killing by the
secretory pathway involves
directed secretion of perforin
and granzyme.  Perforin
polymerases in the target cell
membrane creating a transmembrane pore to facilitate the entry of granzyme into the target cell.
Granzyme is a serine protease responsible for caspase activation, which triggers apoptosis.  It
has recently been proposed that granzyme can cross cell membranes via receptor-mediated
endocytosis and that perforin might allow escape from the endosome (92).  It has also been
suggested that granzyme might have non-caspase targets such as Bcl-2.  Granzyme s ability to
mimic Asp-ase activity of caspases suggests that downstream caspase targets might also be
activated by granzyme (92).  NKT cells recognize a target cell by the lack of an inhibitory
Figure 7- Secretory NK Killing Mechanisms (Adapted from
Devles et al, 2001 (91))
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signaling molecule on the surface of the target cell (See Figure 7). The lack of this molecule
triggers mechanisms that re-orient the NKT cell s internal secretion machinery towards the target
cell (93, 90, 94, 95, 96).  Release of perforin and granzyme is thus directed only against the
target cell.
Invariant T Cell Receptor and Co-stimulatory Markers
NKT cells possess an activated T cell phenotype (i.e. CD69+, CD44high, CD62L, CD5 high,
CD45RBhigh, IL-2R), indicative of a cell type that can rapidly respond to environmental cues (8,
12).
NKT cells have a highly conserved T cell receptor (TCR) referred to as an invariant TCR
(iTCR).  The TCR receptor exists a complex with several other co-receptors, CD3, CD4 or CD8,
CD28 and CD154 (CD40L).  Activation occurs with the ligation of the iTCR and co-stimulatory
signals received from CD28, CD40L or from soluble factors such as IL-12.
The TCR is comprised of a α chain and a β chain each, with variable, joining and
constant regions. The variable regions
of both chains make up the antigen-
binding site.  The structure of the TCR
is similar to an immunoglobulin
molecule (see Figure 8).  The iTCR of
NKT cells is comprised of specific α
and β chains.  In mice the α chain is
Vα14Jα281 and this chain
preferentially pairs with one of three β
chains: Vβ8.2, Vβ7 or Vβ2.
CD3 is closely associated with the TCR (and iTCR) and is essential for TCR signal
transduction.  CD3 is expressed as 3 dimers: ζζ, γε and a εδ (see Figure 8).  Each of these
dimers has an immunoreceptor tyrosine kinase signaling motif (ITAM) that interacts with the
tyrosine kinases Lck, Fyn and Zap-70 to activate signal transduction cascades leading to cytokine
Figure 8- The TCR/CD3 Complex (Adapted from Goldsby et al,
2000 (48))
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secretion.  CD4 and CD8 are other important co-receptors associated with the TCR.  These co-
receptors help to stabilize binding between the MHC complexes and the TCR, and amplify signal
transduction within the T cell.  These receptors are members of the immunoglobulin superfamily
and both CD4 and CD8 define the function of conventional T cells.
CD4+ T cells are T helper cells (Th) that can be divided into 2 categories: T helper 1
(Th1) and T helper 2 (Th2) (see Figure 9).  Th1 T cells mediate cellular immunity and Th2 cells
mediate humoral immunity (see Figure 2).  CD4 T cells are restricted to recognizing antigen
presented by MHC class II molecules.  CD8 T cells are cytotoxic effector T cells (Tc or CTLs) that
kill targeted cells by NK cell-
like mechanisms.  Tc cells
are restricted to MHC class I.
Other CD4+ cells that
regulate tolerance induction
are referred to as Th3 (98)
and Tr cells (99).  These
cells differ in surface
phenotype from Th1 and Th2
cells and are found in the
oral cavity and gut.  Recall
that NKT cells are either
CD4+ or double negative
(DN) and they do not
express CD8.  CD4 on NKT cells serves to amplify signal transduction and stabilizing binding
between CD1d and the iTCR.  T cells require 2 signals for activation (48).  The TCR-CD3
complex binding to the MHC-antigen complex provides one signal.  A second co-stimulatory
molecule provides a second signal.  This second signal prevents uncontrolled T cell activation
and thus prevents autoimmunity (100).  Two important co-stimulatory molecules expressed by T
cells are CD28 and CD154 (CD40L).
Figure 9- An overview of lymphocyte responses (Adapted
from Delves et al, 2001 (97))
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CD28/CD154 (CD40L)
CD28 is expressed on all CD4 T cells and most CD8 T cells.  CD28, also a member of
the immunoglobulin sperfamily, is expressed as a disulphide-linked homodimer.  CD28 is involved
in T cell proliferation, IL-2 production, prevention of T cell anergy, induction of the anti-apoptotic
factor Bcl-xL and differentiation of Th1/Th2 responses (102, 100, 103, 104, 105).  CD28 also
plays a role in stabilizing the generation of the immune synapse between T cells and APCs (106)
serving a dual role as an adhesion and signaling molecule.  The requirement for CD28 co-
stimulation can be bypassed by high antigen concentrations or strong agonist peptides (102).
Activated CD28 may interact with phophatase 2A (PP2A) and upon activation, the CD28 tyrosine
kinase residues are phosphorylated by disassociation with PP2A.  CD28 then activates
phophatidylinositol 3- kinase (PI3K) induces intracellular signaling leading to cytokine production,
proliferation and survival (103).  In
conventional T cells, activation of CD28
also activates cytotoxic lymphocyte
associated molecule-4 (CTLA-4), which
serves as an agonist for the CD28 ligand.
The mechanism by which CTLA-4 inhibits
TCR-CD3 signaling is unknown but it is
believed that CTLA-4 interacts with SHP-
2 phophatase and may dephosphorylate
CD3 (103).  CTLA-4 activation results in the inhibition of ERK and JNK kinases and the inhibition
of NF-KB, AP-1and NF-AT activation.  This CTLA mediated inhibition leads to the cell cycle arrest
and the inhibition of cytokine secretion (103).  The ligand for CD28/CTLA-4 is either B7.1 or B7.2,
which are expressed on APCs.  B7-2 is the dominant co-stimulatory ligand for CD28 during the
initiation of immune responses.  The expression of B7-1/B7-2 on APCs parallels the expression of
CD28/CTLA-4 on T cells (104) suggesting that CD28/B7-2 primes the immune response, while
CTLA-4/B7-1 is responsible for the termination of the immune response (102).
Figure 10-Proposed DC/NKT cell cross-talk (Adapted from
Ikarashi et al, 2002 (101))
26
NKT cells do not express CTLA-4 (108).  Regulation of NKT cell activation is controlled
by NK KIR receptors.  The exact KIR is not known but candidates include Ly49 and
CD94/NKG2A (101).  The ligands on the dendritic cells (DCs) that inhibit NKT cells are the H-2Db
murine self-recognition markers (Class I) (101).  These self-markers inhibit IFN-γ production by
NKT cells, thus inducing tolerance (101).  Immature DCs are capable of inhibiting NKT cell
activation but when subjected to stress (activation by antigen), express B7, which overcomes the
H-2Db-mediated inhibition.  Immature
DCs treated with anti-CD28 antibodies
activated NKT cells (101).  This
proposed regulation is shown in Figure
10.
CD154 (CD40L) is a 32-39kDa
member of the tumor necrosis factor
(TNF) family and is expressed as a
heteromultimeric complex (109, 110,
111).  CD154 is expressed on activated
mature T cells but not on resting T
cells.  CD154 is also found mainly on
CD4 T cells although some CD8 T cells
express CD154 (109).  CD154 ligand is
CD40, found on B cells, APCs and monocytes/macrophages.  This signaling system is implicated
in T cell priming, expansion and maturation into effector cells.  CD40/CD154 plays a role in B cell
proliferation, differentiation and immunoglobulin (Ig) production (109) (111). CD40/CD154 also
plays a role in T cell tolerance, dendritic cell maturation and the differentiation of Th1/Th2 immune
responses (109, 110).
Collectively, these receptors are located in specialized microenviroments referred to as
rafts on the T cell surface (112) and all of the above receptors are recruited into the rafts by
Table 7- Cytokines secreted by NKT cells (Adapted
from Janeway et al, 1999 (107))
Cytokines: Actions
Th1:
IFN-γ
GM-CSF
TNF-α
TNF-b
IL-2
IL-3
Macrophage activation, increased MHC expression
and antigen processing, Ig class switching, inhibits
Th2
Stimulates growth and differentiation of
myleomonocytic lineages
Local inflammation, endothelial activation
Killing, endothelial activation
T cell proliferation
Synergistic action in early hematopoiesis
Th2:
Il-4
IL-5
IL-10
TGF-β
B cell activation, IgE switch, Th1 suppression
Eosinophil growth, differentiation
Inhibits Th1, stimulates MHC Class II, inhibits
cytokine release
Inhibits growth, anti-inflammatory
Chemokines:
Eotaxin
MIP-1α
MIP-1β
Chemoattractant for eosinphils, monocytes and T
cells
Chemoattractant for monocytes, NK and T cells
(Th1>Th2), B cells and dendritic cell
Chemoattractant for monocytes, NK, T cells and
dendritic cell
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CD28.  These domains create specialized local conditions in the T cell membrane which
optimizes signal transduction (113).
NKT cells secrete a variety of Th1, Th2 and Th3 cytokines (see Table 7).  The switch
mechanisms that govern the switch
between cytokine secretion profiles
are poorly understood.  As with
conventional T cells, NKT cells are
activated by a two signal system.
Disrupting expression of either
CD28 or CD154 (CD40L)
profoundly inhibits cytokine
secretion by NKT cells.  Blocking or
genetic knockout of CD28, CD154
(CD40L) or both markedly
decreased production of both IFN-γ
and IL-4 secretion.  These effects
were observed both in vitro and in
vivo (see Figure 11).  Blocking
expression or genetic knockout of CD28 and CD154 (CD40L) is marked by inhibition of anti-
metastatic effects and impairment of α-GalCer serum responses (108, 76).
Figure 11- The Effects of CD28 and CD40 knockouts
on IFN-γ and IL-4 secretion (Adapted from Hayakawa et al, 2001
(108))
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THE ROLE OF NKT CELLS IN VIRAL INFECTION
Viral infection results in the activation of all components of the adaptive immune system.
Effective T cell and B cell responses are required to clear viral infection.  Mice with severe
combined immunodeficiency (SCID) infected by a lytic virus (e.g. vaccina virus) rapidly develop
fatal infections.  Alternatively, when challenged by nonlytic virus (e.g. lymphocytic
choriomeningitis virus) SCID mice develop persistent infections.  Immunocompetent mice infected
under the same conditions (viral dose and route) do not die or fall ill (106).
During the course of a viral infection, locally high levels of antigen can be generated
within infected cells.  The innate immune system can quickly respond to this threat by lysing the
infected cell and processing viral antigens.  These viral antigens are presented by APCs to the
adaptive immune system resulting in T cell and B cell responses.  Because effective T cell and B
cell responses are required for viral clearance, NKT cells are in a unique position to aid in the
immune response.  NKT cells have been implicated in responding to viral challenge in separate
viral models.  NKT cells have been demonstrated to stop viral replication of Hepatitis B virus
(HBV) (84) and activate NK cells to secrete anti-viral cytokines in the liver.  NKT cells also
protected mice from infection with diabetogenic encephalomycarditis virus (EMCV-D) (55).  In
both models, the α-GalCer was delivered by intravenous injection and the precise manner in
which the NKT cells were activated could not be determined.  α-GalCer may have been taken up
and processed by an APC and then presented to NKT cells by CD1d.  NKT cell iTCR activation
requires 2 signals.  The invariant TCR/CD3 complex interacts with CD1d on APCs to provide a
primary signal.  The second signal is dependent
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 on either soluble factors (e.g. IL-12) or stimulation of other surface expresses receptor such as
CD28.
The ligands for CD28 and CTLA-4 are B7.1 (CD80) and B7.2 (CD86) that are expressed
on a variety of APCs (100) (104).  These two ligands function to play a role in the differentiation of
the immune response.  B7 co-stimulation modulates Th2 differentiation, transplant rejection, and
initiation of autoimmune disease (104) (102) (114) (100).  Paradoxically, some Th1 responses are
strongly B7 dependent.  B7 dependent Th1 responses include responses to vesicular stomatitis
virus (VSV), mouse mammary tumor viruses (MMTV), alloantigens, soluble antigens and tumors
(100).  Based on these reports, CD28 could play a role in activation and polarization of NKT cell
responses.
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HYPOTHESIS
Ligation of CD28 triggers production of IFN-γ (Th1 polarization) in NKT cells responding to
Hepatitis B virus infection.
AIM:
Determine if disruption of CD28 gene expression (i.e., gene knockout) in 1.3.32 HBV mice
1. Impairs IFN-γ secretion by NKT cells following challenge by HBV.
2. Inhibits IFN-γ secretion in a DC/NKT cell co-culture assay system.
Significance
Most current treatments for autoimmunity focus on disease symptoms rather than the
abrogation of disease.  Understanding the function of the immune system becomes paramount in
both treating autoimmune disease and in avoidance of side effects of immunotherapy.  NKT cells
have been implicated in a variety of autoimmune disorders and manipulation of these cells could
result in new therapies for these diseases.
Multi-resistant strains of bacteria, parasites and viruses exist in both clinical and
community settings.  Discovery and development of anti-infective drugs is difficult and effective
drug-base anti-viral therapies are limited. By stimulating NKT cells, such infections could be
eradicated without anti-infective pharmacophores.
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Anti-cancer chemotherapy, while successful, has severe side effects.  Among these side
effects are severe immune suppression and inhibition of rapidly dividing non-cancerous cells
(e.g.)hematopoietic stem cells), nausea, vomiting, diarrhea and fatigue.  NKT cells are implicated
in three models of anti-cancer response (71).  Cancer treatment using NKT cells would not
require anti-cancer drugs.
Another unique possibility for NKT cell based treatment would be manipulation of the
CD1 antigen presenting system.  As advocated by Bendelac, manipulation the CD1 antigen
presenting system maybe be of value in developing vaccines for PAMPs (universal vaccines) and
cancer (51).  For example: the immune system (i.e. NKT cells) could be primed against LPS (a
PAMP) in gram negative pathogens and thus protect the recipient against gram negative bacteria.
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EXPERIMENTAL DESIGN
Ligation of CD28 helps to trigger INF-γ (Th1 polarization) in NKT cells during responses
to HBV infection.
The effects on
CD28 knockouts
mice would be
assessed by in vitro
co-culture assays
measuring IFN-γ production and secretion.  The role of CD28 in INF-γ secretion and inhibition of
HBV replication would be measured by in vivo challenge studies.  The experimental design is
summarized in Table 8
Methods and Materials
Generation of transgenic mice
The mice used for this study would be derived from the previously described strain 1.3.32
(115), (84).  This strain of mouse is derived from B6 mouse line and has a HBV transgene
inserted into its genome.  Hepatocytes of this mouse replicate the HBV virus at levels comparable
to chronic hepatitis patients, but without any evidence of cytopathology.  Knockout (KO) strains
generated for this study would be CD28 KO (116), CD1d (116) and IFN-γ KO (84) strains.  Each
of these strains would be produced by insertion of neomycin resistance cassettes as described
(118).  Briefly, ES cells are harvested from the inner-cell mass of blastocysts in superovulating
females and are genetically modified prior to re-insertion into the blastocysts to
Table 8- Experimental Design
Assay type: Assay: Comments:
In vitro
assay
DC/NKT cell co-culture
assay
Measures cytokine secretion in WT and CD28
knockout mice.  Treatments would be vehicle, α-
Gal, α-Man.  Cytokine secretion is measured by
ELISA.
In vivo
assay
HBV transgenic mouse
assay
Used for previous NKT cell work measuring IFN-γ
secretion.  Strains used for assay are WT, CD28,
Jα281 and IFN-γ knockout.  Inhibition of viral
replication would be measured by RPA and
southern blot, while IFN-γ secretion would be
measured by ELISA.
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produce chimeric animals containing the altered gene(s).  First, the ES cells are cultured and the
targeting vector is inserted by electroporation.  All the knockout mice would have their respective
genes disrupted by either insertion or replaced by a neomycin resistance cassette.  The ES cells
are then cultured in the presence of neomycin (the selection agent) so only the ES cells that have
incorporated the neomycin resistance cassette survive.  These clones are then re-introduced into
blastocysts and re-implanted into pseudopregenant female mice.  Coat color markers and
Southern blot analysis is used to confirm that the chimeric mice contain the HBV transgene and
to confirm the knockout of the different genes.  Additional confirmation of the HBV transgene is
determined by detection of hepatitis B e antigen (commercial kit from Abbott Laboratories,
Chicago, IL).  Mating of the chimeric offspring produces heterozygous mice and crossing these
mice results in mice homozygous for the knockouts.
The IFN-γ HBV transgenic mice are viable (84) but it is unknown whether the CD28 KO
HBV transgenic mice or the CD1d KO HBV transgenic mice would be viable.  The combinations
of both knockouts could result in a lethal phenotype that would not develop or eventually die.  If
these mice strains are not viable, the KO strains for CD28, CD1d and IFN-γ could all be
purchased from the Jackson Laboratory (Bar Harbor, MA) with the wild type B6 parent and used
in HBV infection studies.
Isolation of NKT cells
Liver NKT cells would be isolated as previously described (84) (117).  Briefly, the liver would be
pressed through a steel mesh, then suspended and washed in RPMI media.  Mononuclear cells
would be isolated by Ficoll-Isopaque density gradient centrifugation.  Mononuclear cells would be
collected from the interface, washed and analyzed by flow cytometry to isolate the NKT cells.
The NKT cells would be isolated using modification of the method of Bendelac et al (15)
that isolated ~100% of human NKT cell population from peripheral blood.  For the isolation of
murine NKT cells, the three monoclonals used would be directed against NK1.1, α-GalCer:CD1d
tetramers and finally Vα14.  The rationale for the choice of monoclonal antibodies is as follows:
NK1.1 is the main NK receptor expressed on NKT cells.  α-GalCer:CD1d tetramers are specific
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for CD1d restricted TCR (15) and Vα14 is only found on the TCR of NKT cells Once the NKT
cells are isolated, they will be separated electromagnetically into CD4+ and DN populations of
NKT cells.
Generation of dendritic cells
Dendritic cells (DCs) would be derived as described by Ikarashi et al (101).  Bone marrow
derived DCs would be propagated from BM progenitor cells in culture medium containing rmGS-
CSF and rmIL-4 (R&D Systems).  At 6 days of culture, DCs would be induced to mature by
stimulation with anti-CD16 and anti-CD32 antibodies.  CD16 mediates phagocytosis and
antibody-dependent cell-mediated cytotoxicity.  CD32 is a low affinity Fc receptor for aggregated
immunoglobulin and immune complexes.  Treatment with these anti-antibodies would simulate an
infection causing the maturation of the immature DCs in the cell population.  The DCs should up-
regulate the expression of their surface receptors especially those associated with antigen
presentation and immune cell activation (e.g. MHC I & II, CD1d, CD40, CD80 and CD86).  These
mature DCs would be isolated by flow cytometry gated for CD40, MHC Class II, CD1d, and CD80
or CD86 expression as described (101).
α-Galactosylceramide
α-GalCer would be prepared as described (84).  α-GalCer in DMSO (10 ug/mL) would be diluted
in 1xPhophate buffered saline to 2 ug/mL.
IFN-γ ELISA assay
IFN-γ would be quantified by using a commercially available ELISA kit from BD PharMingen
(OptEIA Mouse IFN-γ Kit) (119).
Ribonuclease protection assay/southern blot assay
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Messenger RNA from NKT cells would be isolated by guanidinium isothiocyanate (GITC):
phenol:chloroform extraction.  This method lyses the cells, precipitates the cellular debris and
DNA.  The RNA would be isolated by ethanol precipitation resulting in a highly purified pool of
cellular RNA.  Using this pool of RNA, both RNA protection assays (RPA) and southern blot
assays will be performed.  RNase Protection assays are performed by hybridizing the sample
RNA with digoxygenin labeled probes, then RNAase digestion (120).  The protected samples
would be resolved by PAGE electrophoresis and photographed on an image analysis system.  A
second RNA sample would be used to construct a cDNA library by RT-PCR.  The DNA library
would be digested with restriction enzymes (5 units/ mg DNA, 8 hours) and concentrated with an
ethanol precipitation.  Next the DNA would be separated on a 0.7% agarose 0.5x TBE gel at low
voltage.    The DNA would next be transferred onto a positively charged nylon hybridization
membrane by downward capillary transfer (24 hours).  Hybridization would be performed in a
hybridization bottle.  After pre-wetting the membrane with hybridization buffer for 2 minutes, fresh
hybridization buffer with the radiolabeled probe as described (115).  The membrane would then
be wash once in 2x SSC buffer for 15 minutes and then in 0.1x SSC buffer plus 0.1% SDS for 4
hours.  At the end of the incubation the membrane would be washed in 0.1x SSC buffer, air-dryed
and glued 3MM paper.  The membrane would be imaged using audioradiography and the viral
DNA quantified.  The probes used for both assays are described on the Mouse Genome
Database (MGD) website or in Guidotti et al (115).
DC/NKT cell co-culture assay
Hepatic NKT cells would be cultured with mature DCs (described above) follow the
previously described method (101).  Prior to NKT cell addition, the DCs would be pulsed with 10-
ng/mL α-GalCer or 10 ng/mL α-mannosylceramide (α-ManCer) to activate the DCs.
Measurement of IFN-γ secretion would be by ELISA as described above.  ELISA quantification of
IFN-γ would confirm that α-GalCer is activating the NKT cells.  Two separate assays would be
performed, one with CD4 NKT cells and one with DN NKT cells
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Figure 12-HBV Challenge Assay Flow Chart
Murine HBV challenge assay
The in vivo HBV challenge
assay would be set up as described by
Kakimi et al (84).  The assay would use
the wild type (WT) mice (positive
control), IFN-γ KO mice (negative
control), CD1d KO mice (-NKT cell
control) and the CD28 KO mice (test
strain).  The assay would be performed
as described (84).  Briefly, the mice would be maintained in pathogen-free rooms with strict
barrier conditions.  Conventional T cell depletion would be accomplished by injection of anti-
mouse CD4 mAb and anti-mouse CD8 mAb 24 hours prior to α-GalCer stimulation.  This assay
would determine the effects of CD28 KO on DN NKT cells.  To determine the effect of CD4 NKT
cells, the anti-CD4 monoclonal antibody would not be injected into a set of the α-GalCer treated
CD28 KO mice, CD1d KO mice, IFN-γ KO mice and WT control mice.  The mice would then be
dosed with 2 ug IV of a-GalCer and sacrificed at 1 day or PBS vehicle control.  The livers would
be extracted and frozen (-80°C) for later RPA and southern blot analysis.  The serum levels of
IFN-γ would also be determined by ELISA assay (above).  The flow chart for the procedure is
shown in Figure 12.
Test Design and Predicted Results
In vitro IFN-γ secretion by co-culture of DC and NKT cells
The co-culture experiments would be performed as described in the methods section.
Mature dendritic cells would be pulsed with α-GalCer and then cultured with NKT cells.
37
These experiments would measure the ability
of stimulated NKT cells to secrete IFN-γ in vitro.
Both CD4 and DN NKT cells would be assayed
and the IFN-γ levels secreted by each would be
compared.  The assays could be executed two ways.  The first would involve extraction of NKT
cells from WT mice, blocking CD28 with blocking anti-CD28 mAbs (108), and executing the co-
culture assay.  The second option is to extract NKT cells from both the WT and the CD28 KO
mice and then performs the co-culture experiments.  Data between the parent and the mutant
could be compared.  The test treatments would be as follows: vehicle (1xPBS), α-GalCer, α-
ManCer (negative control).  These treatments would be administered to both WT and CD28
blocked/KO NKT cells.  The vehicle treated and α-ManCer NKT cells should have little to no IFN-
γ secretion while the WT NKT cells should secrete high levels of IFN-γ.  The results of the in vitro
work are summarized in Table 9.  Recent work by Benlagha et al (121) suggests that murine NKT
cells might undergo a Th2 (CD4/DN NKT cells) to Th1 (CD4 mainly) conversion as they migrate
to the periphery.  If this were the case the CD4 NKT cells would secrete higher levels of IFN-γ
than DN NKT cells (121).
In vivo inhibition of HBV replication
The impact of CD28 knockout on IFN-γ and Th1 polarization by NKT cells would be
assessed using HBV transgenic mice.  The experiment would consist of a single intravenous
dose of α-GalCer to activate NKT cells and determining the effects of the mutations on IFN-γ
secretion.  The assay would use wild type (WT) mice (positive control), IFN-γ KO mice (negative
control), CD1d KO (NKT cell negative control) and the CD28 KO mice (test strain).  Anti-CD4 and
anti-CD8 monoclonal antibodies would be added to deplete conventional T cells in the mice.  By
treating the mice with these antibodies only the DN NKT cells could be assayed.
To determine the affect of CD28 KO on CD4 NKT cells, the anti-CD4 monoclonal
antibody would not be added to a second set of mice.  If anti-CD4 monoclonal antibody is added
to the test treatment the CD4 NKT cells would be depleted with the conventional CD4 T cells.
Table 9- Predicted outcome of in vitro
DC/NKT cell co-culture assays
NKT cell Type: Treatment: IFN-γ secretion:
Vehicle ---
α-GalCer +++Wild Type
α-ManCer ---
Vehicle ---
α-GalCer ---CD28 Knockout
α-ManCer ---
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The second experiment would be set up the same as the DN experiment with one difference.  In
order determine the level of IFN-γ secretion by CD4 NKT cells, a baseline IFN-γ measurement
against CD1d KO mice would be performed.  This base line measurement would determine the
amount of IFN-γ secretion by both conventional T cells.
In addition, there would be a WT vehicle control mouse (dosed with 1x PBS) in both
experiments.  One day after activation of NKT cells by α-GalCer the mice would be sacrificed,
levels of viral replication and IFN-γ transcription assessed by RPA and Southern Blot analysis.
ELISA would be used to determine the serum levels of IFN-γ.
Based on previous data (84) generated with DN NKT cells, the WT vehicle control mice
should show low to no levels of IFN-γ as detected by ELISA, RPA or Southern Blot.  There should
also be high levels of viral replication as measured by RPA and Southern Blot.  The WT mice + α-
GalCer should show inhibition of viral replication and have elevated levels of IFN-γ.  There should
be elevated levels of IFN-γ transcription as measured by RPA and Southern blot.  The CD28 mice
should be similar to the vehicle control mice, with no to low levels of IFN-γ compared to WT
treated mice, as well as no to low levels of IFN-γ transcription.  Finally, IFN-γ KO mice should be
similar to the vehicle control, displaying uninhibited viral replication, undetectable levels of IFN-γ
secretion and replication.
The results of the CD4 NKT cells would have to be determined by subtracting the
baseline IFN-γ secretion of conventional T cells from the WT positive control.  The results should
mirror the DN NKT cells.  If murine NKT cells do undergo a Th2 (CD4/DN NKT cells) to Th1 (CD4
mainly) conversion, CD4 NKT cells would secrete higher levels of IFN-γ than DN NKT cells (121).
The predicted results of the in vivo work are summarized in Table 10.
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The IFN-γ KO HBV
transgenic mice have been
previously described (84).
The CD28 and CD1d KO
HBV transgenic mice have
not been reported in the
literature.  The effects of both
CD28 and CD1d knockouts
in this HBV background are unknown.  It is possible that these knockouts could be lethal to these
mice.  If these mouse strains are not viable, the hypothesis will have to be tested in non-HBV
transgenic mice KO mice (see Methods and Materials).  The experiment could be run as
described except that the mice would be inoculated with a lethal dose of HBV and then stimulated
with α-GalCer.  The results should be the same as described for the HBV transgenic mice.
Test treatments IFN-γ Viral Replicationinhibition
Treatment Blocking mAb ELISA RPA RPA Southern
CD4 & CD8 --- --- --- ---WT + vehicle CD4 --- --- --- ---
CD4 & CD8 +++ +++ +++ +++WT + α-
GalCer CD4 +++ +++ +++ +++
CD4 & CD8 --- --- --- ---CD28 KO + α-
GalCer CD4 --- --- --- ---
CD4 & CD8 --- --- --- ---IFN-γ KO + α-
GalCer CD4 --- --- --- ---
CD4 & CD8 --- --- --- ---CD1d KO + α-
GalCer CD4 + + + +
Table 10 — Predicted in vivo results of HBV Transgenic
mouse studies
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CONCLUSIONS
CD28 knockout should impair IFN-γ secretion and thus block the NKT cell mediated
response to HBV infection.  The loss of α-GalCer induced antimetastatic effect in CD28 KO mice
is paralleled by a loss in IFN-γ secretion (108).  IFN-γ plays a crucial role in the clearance of HBV
infection (84).  The NKT cell IFN-γ secretion (Th1 polarization) is responsible for inhibiting viral
replication and for activating NK cells to aid in viral clearance.
Previous work with HBV transgenic mice has illustrated the importance of NKT cell IFN-γ
secretion and Th1 polarization in response to HBV infection (84).  The inhibition of HBV
replication was demonstrated to be dose and time dependent (84).  The described system
provides a unique opportunity to determine the role of co-receptors in IFN-γ and Th1 polarization
of NKT cells in response to viral infection.  Work by Hayakawa et al (108) has illustrated the
central role of CD28 in IFN-γ secretion and thus Th1 polarization.  These previous studies
demonstrated that inhibiting INF-γ secretion abolishes the anti-metastatic responses of NKT cells.
There are currently no reports in the literature studying infection in NKT cell KO mice.  CD28
stimulation results in transcriptional regulation of the IFN-γ gene.  This has been demonstrated in
conventional T cells (108).  The effects of CD154 (CD40L) and IL-12 blocking on IFN-γ production
also emphasize the role of CD28.  CD28 co-stimulation stabilizes expression of CD154 (CD40L)
on conventional T cells thus facilitating CD40-CD154 (CD40L) interactions.  In turn, CD40-
mediated activation up-regulates CD80/CD86 (B7.1/B7.2) expression on DCs and enhances
CD28-CD80/86 interactions (108).  The concept that CD28 might serve to stabilize and create a
microenvironment favorable for signaling has been advanced by Bromely et al (122).
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Study of co-stimulatory receptors in NKT cells could lead to technologies and
therapies that could selectively stimulate NKT cell cytokine secretion.  Such technologies would
have broad applications in immune regulation, infection treatment and cancer treatment.
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